Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide

    CAG

    RecoveryPreclinical

    Also known as: CAG peptide, Collagen-derived peptide, Gly-Hyp-Pro related peptide

    CAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications. In the context of research peptide vendors, CAG refers to a specific short peptide sequence with proposed activity in cartilage and collagen tissue modulation.

    Half-Life: UnknownRoute: Subcutaneous, Intraarticular
    Last reviewed:
    Recovery
    Category
    Preclinical
    Research Stage

    Overview

    At A Glance

    Mechanism

    CAG peptide is proposed to modulate chondrocyte behavior and extracellular matrix components in cartilage tissue. Short collagen-derived peptides (Pro-Hyp, Gly-Pro-Hyp) have documented activity in stimulating hyaluronic acid production and collagen synthesis in chondrocytes and f

    Half-Life
    Unknown
    Dosing
    once daily
    Dose Range
    0mcg
    Routes
    SubcutaneousIntraarticular
    Common Vials
    5mg10mg
    Potential Benefits
    Potential cartilage and connective tissue support via collagen pathway modulationChondrocyte activity modulation in joint tissue research modelsMay complement BPC-157 and TB-500 in joint repair stacking protocols
    Safety Notes
    Common
    Limited adverse event data available
    Serious
    No clinical safety data — strictly preclinical

    Overview

    CAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications. In the context of research peptide vendors, CAG refers to a specific short peptide sequence with proposed activity in cartilage and collagen tissue modulation. CAG peptide research is in early preclinical stages with limited published clinical data. It is often compared to other joint/connective tissue peptides like BPC-157, TB-500, and the Khavinson bioregulator Cartalax. The precise mechanism depends on the specific sequence sold by a given vendor.

    Chemical Information

    IUPAC Name

    Not yet available

    CAS Number

    Not yet available

    Molecular Formula

    Not yet available

    Molecular Mass

    Not yet available

    Chemical data is being compiled for this compound.

    Dosing & Protocols

    Unlock Dosing Protocols

    Free account gets you:

    • View beginner, intermediate & advanced protocols
    • See weight-based dosing calculations
    • Access cycle length & frequency data

    2,800+ researchers already in

    Research

    Unlock Research Data

    Free account gets you:

    • Browse PubMed study summaries
    • See clinical trial phases & results
    • Access mechanism of action details

    2,800+ researchers already in

    Interactions

    Interaction and contraindication data is being compiled for CAG. Check back soon.

    General Safety Note

    Always consult a qualified healthcare professional before combining research compounds. Interactions may exist that are not yet documented.

    No listings found for CAG.

    Get CAG Price Drop Alerts

    Set a target price and we'll notify you when any vendor drops below it.

    Sign in to leave a review

    Reviews on BodyHackGuide are tied to verified user accounts and moderated before publishing. Sign in (free, no spam) to share your experience with CAG.

    Current low
    $99.00
    as of Apr 22, 2026
    7-day low
    no 7d data yet
    30-day low
    no 30d data yet
    30-day change
    baseline building

    Tracking since Apr 22, 2026 · 2 data points

    Related Compounds

    View All

    ARA-290

    RecoveryPreclinical

    ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.

    1 mg - 4 mg subcutaneous, 3x per week
    52 studiesView Profile

    BPC-157/TB-500 Blend

    RecoveryPreclinical

    Combined healing peptide blend.

    t½ BPC-157: ~4 hours; TB-500: ~2–3 hours BPC-157: 250–500 mcg + TB-500: 750–2500 mcg per injection, typically pre-blended at a fixed ratio
    PreclinicalView Profile

    Bronchogen

    RecoveryPreclinical

    Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.

    10 mg oral capsule, 1-2 daily for 10-30 days
    7 studiesView Profile

    Cardiogen

    RecoveryPreclinical

    Cardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.

    10 mg oral capsule, 1-2 daily for 10-30 days
    9 studiesView Profile

    Cartalax

    RecoveryPreclinical

    Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.

    10 mg oral capsule, 1-2 daily for 10-30 days
    6 studiesView Profile

    Chonluten

    RecoveryPreclinical

    Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St.

    10 mg oral capsule, 1-2 daily for 10-30 days
    1 studiesView Profile

    View Full Dosage Guide →

    Protocols, calculator & safety for CAG

    Research Score

    45

    0 PubMed studies

    Quality Indicators

    Data Completeness

    50%
    Description
    Mechanism of Action
    Chemical Data
    Dosing Protocols
    Safety Profile
    PubMed Studies
    Interactions
    Vendor Listings

    Quick Facts

    Half-Life

    Unknown

    Administration

    Subcutaneous, Intraarticular

    Trial Phase

    Preclinical

    Safety Profile

    Common Side Effects

    • Limited adverse event data available

    Research Disclaimer

    This information is for educational and research purposes only. Not intended as medical advice. Consult a healthcare professional before use.

    Frequently Asked Questions

    What is CAG used for in research?

    CAG (often referring to a collagen-derived or cartilage-targeting peptide sequence) is a short research peptide studied for connective tissue and joint applications. In the context of research peptide vendors, CAG refers to a specific short peptide sequence with proposed activity in cartilage and collagen tissue modulation. CAG peptide research is in early preclinical stages with limited published clinical data. It is often compared to other joint/connective tissue peptides like BPC-157, TB-500, and the Khavinson bioregulator Cartalax. The precise mechanism depends on the specific sequence sold by a given vendor.

    What forms does CAG come in?

    CAG is available in vials, capsules, and sprays forms.

    How much does CAG cost?

    Pricing varies by vendor and form.

    How do I compare CAG vendors?

    Compare prices, payment methods, shipping, and COA scores across 0 vendors.

    Research Tools

    Related Compounds

    View All

    ARA-290

    RecoveryPreclinical

    ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without activating the classical hematopoietic EPO receptor that drives red blood cell production.

    1 mg - 4 mg subcutaneous, 3x per week
    52 studiesView Profile

    BPC-157/TB-500 Blend

    RecoveryPreclinical

    Combined healing peptide blend.

    t½ BPC-157: ~4 hours; TB-500: ~2–3 hours BPC-157: 250–500 mcg + TB-500: 750–2500 mcg per injection, typically pre-blended at a fixed ratio
    PreclinicalView Profile

    Bronchogen

    RecoveryPreclinical

    Bronchogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.

    10 mg oral capsule, 1-2 daily for 10-30 days
    7 studiesView Profile

    Cardiogen

    RecoveryPreclinical

    Cardiogen is a short synthetic peptide developed in Russia by Vladimir Khavinson and his collaborators at the St.

    10 mg oral capsule, 1-2 daily for 10-30 days
    9 studiesView Profile

    Cartalax

    RecoveryPreclinical

    Cartalax is a short synthetic peptide developed in Russia by Vladimir Khavinson and colleagues at the St.

    10 mg oral capsule, 1-2 daily for 10-30 days
    6 studiesView Profile

    Chonluten

    RecoveryPreclinical

    Chonluten is a bioregulator preparation originating from Vladimir Khavinson's St.

    10 mg oral capsule, 1-2 daily for 10-30 days
    1 studiesView Profile

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free

    Need bloodwork before starting?

    Full hormone + metabolic panels from Anabolic Insights. Code CHONCH for first-order discount.

    ResearchChemHQ BPC-157 500mcg × 60 capsules bottle
    IN STOCK · COA PER BATCH

    BPC-157 Caps

    60 caps × 500mcg. HPLC + COA on every batch, ≥99% purity. Same molecule as the vials, just oral so it travels. code REDDIT stacks with their 5-vial 20% off and 10-vial 40% off tiers.

    COUPON CODEREDDIT
    Grab a bottle →
    Research use only. Not for human consumption.|BodyHackGuide promotes vendors. We do not sell these products.